Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Interest & Investment Income (2020 - 2023)

Alx Oncology Holdings' Interest & Investment Income history spans 4 years, with the latest figure at $3.0 million for Q4 2023.

  • For Q4 2023, Interest & Investment Income rose 65.74% year-over-year to $3.0 million; the TTM value through Dec 2023 reached $10.6 million, up 148.92%, while the annual FY2025 figure was $4.0 million, 57.68% down from the prior year.
  • Interest & Investment Income for Q4 2023 was $3.0 million at Alx Oncology Holdings, up from $2.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.0 million in Q4 2023 and bottomed at -$226000.0 in Q3 2020.
  • The 4-year median for Interest & Investment Income is $504500.0 (2020), against an average of $944750.0.
  • The largest annual shift saw Interest & Investment Income plummeted 97.32% in 2021 before it skyrocketed 34350.0% in 2022.
  • A 4-year view of Interest & Investment Income shows it stood at $784000.0 in 2020, then tumbled by 97.32% to $21000.0 in 2021, then soared by 8504.76% to $1.8 million in 2022, then surged by 65.74% to $3.0 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Interest & Investment Income are $3.0 million (Q4 2023), $2.7 million (Q3 2023), and $2.7 million (Q2 2023).